SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS BY 20% IN CERTAIN ADULTS

The purpose and significance of semaglutide effect on the cardiovascular outcome in order to investigate if the semaglutide 2.4 mg, long-acting GLP-1 RA, is more effective than a placebo in reducing cardiovascular event in the individuals having establish cardiovascular disease who are also obese and do not yet have type II diabetes. Adherence to lifestyle guidelines aimed at reducing cardiovascular risk is provided for both semaglutide and placebo (Mares, Chatterjee, & Mukherjee, 2022).